PSYENCE

Live / Applied — Fifth extension granted (statement of use) (as of 12 Nov 2025)

What this means for you

Not registered yet, but its 25 May 2021 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
90732485
Mark type
Stylized text
Filed
25 May 2021
Published for opposition
14 Mar 2023
Attorney of record
Amy J Benjamin

Goods and services

  • Class 005 — Pharmaceuticals: Anti-epileptic pharmaceutical preparations; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia and bipolar disorders; pharmaceutical preparations for the treatment of smoking cessation; pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; pharmaceutical preparations for the treatment of the diseases, disorders and infections of the central nervous system namely brain, movement, ocular motility and spinal cord diseases; pharmaceutical preparations for the relief of pain; preparations for the treatment of mental health disorders; pharmaceutical preparations and herbal supplements for enhancing mental health; pharmaceutical preparations, namely cognitive enhancers for the treatment of mental health disorders; herbal supplements, namely cognitive enhancers; dietary supplements for enhancing mental health, and for the treatment of mental health disorders; dietary and nutritional supplements for alleviating symptoms experienced in the palliative care setting, namely, nausea, anorexia, cachexia, severe intractable pain, severe depressed mood, and insomnia; plant-based supplements for aiding general health, well-being and cognitive function
  • Class 029 — Meats and processed foods: Dried edible fungi; dried edible mushrooms; dried edible mushrooms; edible fungi oils not containing psilocybin or psilocin, fungal extracts for use as ingredients of nutritional supplements; fruit jellies not being confectionary
  • Class 031 — Natural agricultural products: Fresh edible fungi; fresh edible mushrooms; fresh mushrooms; unprocessed mushrooms
  • Class 042 — Scientific and technological services: Research and development in the fields of neurological conditions and their treatment and psychological conditions and their treatment; basic and clinical research in the fields of plant-based medicines and psychedelics; research and development in the field of holistic medicines, natural medicine, psychedelics and nootropics; research and development of treatments for mental health conditions; pharmaceutical research and development in the field of psilocybin; research and development in the field of psilocybin, holistic medicines, natural medicine, psychedelics and nootropics; research and development of psilocybin-based treatments for mental health conditions; scientific research in the nature of conducting clinical trials for others in the field of medicine and mental health; providing scientific research information in the field of psilocybin, psychoactive products, psychedelics and nootropics

Owner

Prosecution history

  • 12 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 12 Nov 2025 — SOU EXTENSION 5 GRANTED
  • 07 Nov 2025 — SOU EXTENSION 5 FILED
  • 08 Nov 2025 — SOU TEAS EXTENSION RECEIVED
  • 06 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 05 May 2025 — SOU EXTENSION 4 GRANTED
  • 05 May 2025 — SOU EXTENSION 4 FILED
  • 05 May 2025 — SOU TEAS EXTENSION RECEIVED
  • 06 Dec 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 06 Dec 2024 — SOU EXTENSION 3 GRANTED
  • 11 Nov 2024 — SOU EXTENSION 3 FILED
  • 06 Dec 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
  • 11 Nov 2024 — SOU TEAS EXTENSION RECEIVED
  • 30 Oct 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 30 Oct 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

View this trademark record on Marksy